Published Online
on May 23, 2005

A more recent version of this article appeared on June 14, 2005

This Article Free upon publication Full Text (PDF) All Versions of this Article: 111/23/3016    most recent CIRCULATIONAHA.105.557652v1 Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Grundy, S. M. Search for Related Content PubMed PubMed Citation Articles by Grundy, S. M. Related Collections Other arteriosclerosis Related Article

Submitted on ,
Accepted on ,

The Issue of Statin Safety. Where do We Stand?

Scott M. Grundy MD, PhD^*

From the Center for Human Nutrition and the Departments of Clinical Nutrition and Internal Medicine, University of Texas Southwestern Medical Center at Dallas.

^* To whom correspondence should be addressed. E-mail: scott.grundy{at}utsouthwestern.edu.

Related Article:

The Safety of Rosuvastatin as Used in Common Clinical Practice: A Postmarketing Analysis

Alawi A. Alsheikh-Ali, Marietta S. Ambrose, Jeffrey T. Kuvin, and Richard H. Karas
Circulation 2005 111: 3051-3057. [Abstract] [Full Text]

This article has been cited by other articles:

				M. Rajaram Hepatitis, rhabdomyolysis and multi-organ failure resulting from statin use BMJ Case Reports, February 2, 2009; 2009(jan27_1): bcr0720080412 - bcr0720080412. [Abstract] [Full Text]

				R. H. Samson The Role of Statin Drugs in the Management of the Peripheral Vascular Patient Vascular and Endovascular Surgery, August 1, 2008; 42(4): 352 - 366. [Abstract] [PDF]

				M. Settergren, F. Bohm, L. Ryden, and J. Pernow Cholesterol lowering is more important than pleiotropic effects of statins for endothelial function in patients with dysglycaemia and coronary artery disease Eur. Heart J., July 2, 2008; 29(14): 1753 - 1760. [Abstract] [Full Text] [PDF]

				M. Al-Shabrawey, M. Bartoli, A. B. El-Remessy, G. Ma, S. Matragoon, T. Lemtalsi, R. W. Caldwell, and R. B. Caldwell Role of NADPH Oxidase and Stat3 in Statin-Mediated Protection against Diabetic Retinopathy Invest. Ophthalmol. Vis. Sci., July 1, 2008; 49(7): 3231 - 3238. [Abstract] [Full Text] [PDF]

				J L Walker, G H Smith, M S Gaston, and C M Robinson Spontaneous compartment syndrome in association with simvastatin-induced myositis Emerg. Med. J., May 1, 2008; 25(5): 305 - 306. [Abstract] [Full Text] [PDF]

				K. Josan MD, S. R. Majumdar MD MPH, and F. A. McAlister MD MSc The efficacy and safety of intensive statin therapy: a meta-analysis of randomized trials Can. Med. Assoc. J., February 26, 2008; 178(5): 576 - 584. [Abstract] [Full Text] [PDF]

				J. R. Holman Some Docs in Denial About Statin Side Effects DOC News, December 1, 2007; 4(12): 1 - 12. [Full Text]

				G. A. Schmidt, J. D. Hoehns, J. L. Purcell, R. L. Friedman, and Y. Elhawi Severe Rhabdomyolysis and Acute Renal Failure Secondary to Concomitant Use of Simvastatin, Amiodarone, and Atazanavir J Am Board Fam Med, July 1, 2007; 20(4): 411 - 416. [Abstract] [Full Text] [PDF]

				An Analysis of Rosuvastatin's Safety Record Journal Watch Cardiology, June 10, 2005; 2005(610): 1 - 1. [Full Text]